| References: |
TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges. Importantly, CLL BMSCs could not protect the leukemic B cells from TP-0903-induced apoptosis. A marked reduction of the antiapoptotic proteins Mcl-1, Bcl-2, and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition. Finally, combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis.Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL. For the detailed information of TP-0903, the solubility of TP-0903 in water, the solubility of TP-0903 in DMSO, the solubility of TP-0903 in PBS buffer, the animal experiment (test) of TP-0903, the cell expriment (test) of TP-0903, the in vivo, in vitro and clinical trial test of TP-0903, the EC50, IC50,and affinity,of TP-0903, For the detailed information of TP-0903, the solubility of TP-0903 in water, the solubility of TP-0903 in DMSO, the solubility of TP-0903 in PBS buffer, the animal experiment (test) of TP-0903, the cell expriment (test) of TP-0903, the in vivo, in vitro and clinical trial test of TP-0903, the EC50, IC50,and affinity,of TP-0903, Please contact DC Chemicals. |
